Vir Biotechnology, Inc. Assets, Fair Value Adjustment
Vir Biotechnology, Inc. (VIR) reported Assets, Fair Value Adjustment of $1.89 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
us-gaap:AssetsFairValueAdjustment · last filed 2026-08-05
- Vir Biotechnology, Inc. assets, fair value adjustment for the quarter ending 2026-06-30 was $1.72M, a 49.05% decline year-over-year.
- Vir Biotechnology, Inc. assets, fair value adjustment for the quarter ending 2026-03-31 was $170.00K.
- Vir Biotechnology, Inc. assets, fair value adjustment for the quarter ending 2025-12-31 was $2.61M, a 122.35% increase year-over-year.
- Vir Biotechnology, Inc. assets, fair value adjustment for the quarter ending 2025-09-30 was -$1.33M.
- Vir Biotechnology, Inc. assets, fair value adjustment for fiscal 2025 was -$1.73M, a 131.28% decline from fiscal 2024.
- Vir Biotechnology, Inc. assets, fair value adjustment for fiscal 2024 was $5.53M, a 74.74% decline from fiscal 2023.
- Vir Biotechnology, Inc. assets, fair value adjustment for fiscal 2023 was $21.89M, a 80.31% decline from fiscal 2022.
- Vir Biotechnology, Inc. assets, fair value adjustment for fiscal 2022 was $111.14M.
| Period end | Assets, Fair Value Adjustment 3 month | Assets, Fair Value Adjustment 6 month | Assets, Fair Value Adjustment 9 month | Assets, Fair Value Adjustment 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $1.89M 10-Q · filed 2026-08-05 | $4.50M derived: sum of 3 quarters · filed 2026-08-05 | $3.16M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $170.00K 10-Q · filed 2026-05-07 | $2.78M derived: sum of 2 quarters · filed 2026-05-07 | $1.44M derived: sum of 3 quarters · filed 2026-05-07 | $4.82M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $2.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $1.27M derived: sum of 2 quarters · filed 2026-02-23 | $4.65M derived: sum of 3 quarters · filed 2026-08-05 | -$1.73M 10-K · filed 2026-02-23 |
| 2025-09-30 | -$1.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $2.05M derived: sum of 2 quarters · filed 2026-08-05 | -$4.33M 10-Q · filed 2025-11-05 | -$3.16M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $3.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$3.00M 10-Q · filed 2026-08-05 | -$1.83M derived: sum of 3 quarters · filed 2026-08-05 | -$2.96M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$6.38M 10-Q · filed 2026-05-07 | -$5.21M derived: sum of 2 quarters · filed 2026-05-07 | -$6.34M derived: sum of 3 quarters · filed 2026-05-07 | -$6.77M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $42.00K derived: sum of 2 quarters · filed 2026-02-23 | -$387.00K derived: sum of 3 quarters · filed 2026-02-23 | $5.53M 10-K · filed 2026-02-23 |
| 2024-09-30 | -$1.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$1.56M derived: sum of 2 quarters · filed 2025-11-05 | $4.36M 10-Q · filed 2025-11-05 | $5.35M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | -$429.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $5.49M 10-Q · filed 2025-08-06 | $6.48M derived: sum of 3 quarters · filed 2026-02-23 | $9.19M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | $5.92M 10-Q · filed 2025-05-08 | $6.91M derived: sum of 2 quarters · filed 2026-02-23 | $9.61M derived: sum of 3 quarters · filed 2026-02-23 | $14.70M derived: sum of 4 quarters · filed 2026-02-23 |
| 2023-12-31 | $993.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $3.70M derived: sum of 2 quarters · filed 2026-02-23 | $8.79M derived: sum of 3 quarters · filed 2026-02-23 | $21.89M 10-K · filed 2026-02-23 |
| 2023-09-30 | $2.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $7.79M derived: sum of 2 quarters · filed 2024-11-04 | $20.89M 10-Q · filed 2024-11-04 | $12.02M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $5.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $18.19M 10-Q · filed 2024-08-01 | $9.31M derived: sum of 3 quarters · filed 2025-02-27 | $22.90M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $13.10M 10-Q · filed 2024-05-03 | $4.22M derived: sum of 2 quarters · filed 2025-02-27 | $17.82M derived: sum of 3 quarters · filed 2025-02-27 | $29.20M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$8.88M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $4.71M derived: sum of 2 quarters · filed 2025-02-27 | $16.10M derived: sum of 3 quarters · filed 2025-02-27 | $111.14M 10-K · filed 2025-02-27 |
| 2022-09-30 | $13.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $24.98M derived: sum of 2 quarters · filed 2023-11-03 | $120.02M 10-Q · filed 2023-11-03 | $146.04M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | $11.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $106.43M 10-Q · filed 2023-08-04 | $132.45M derived: sum of 3 quarters · filed 2024-02-26 | -$31.62M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | $95.04M 10-Q · filed 2023-05-08 | $121.06M derived: sum of 2 quarters · filed 2024-02-26 | -$43.01M derived: sum of 3 quarters · filed 2024-02-26 | -$43.01M derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | $26.02M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | -$138.05M derived: sum of 2 quarters · filed 2024-02-26 | -$138.05M derived: sum of 3 quarters · filed 2024-02-26 | -$138.05M 10-K · filed 2024-02-26 |
| 2021-09-30 | -$164.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$164.07M derived: sum of 2 quarters · filed 2022-11-03 | -$164.07M 10-Q · filed 2022-11-03 | -$164.07M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $0.00 10-Q · filed 2022-08-09 | $0.00 derived: sum of 3 quarters · filed 2023-02-28 | |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-05 | $0.00 derived: sum of 2 quarters · filed 2023-02-28 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $0.00 10-K · filed 2023-02-28 | ||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |